While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .
A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia.
OBJECTIVE To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain  associated with fibromyalgia ( FM ) and for management of FM . METHODS This multicenter , double-blind , placebo-controlled trial r and omly assigned 748 patients with FM to receive placebo or pregabalin 300 , 450 , or 600 mg/day ( dosed twice daily ) for 13 weeks . The primary outcome variable for study objective 1 , symptomatic relief of pain associated with FM , was comparison of endpoint mean pain scores between each pregabalin group and placebo . The outcome variable for study objective 2 , management of FM , included endpoint mean pain scores , Patient Global Impression of Change ( PGIC ) , and Fibromyalgia Impact Question naire (FIQ)-Total Score . Secondary outcomes included assessment s of sleep , fatigue , and mood disturbance . RESULTS Patients in all pregabalin groups showed statistically significant improvement in endpoint mean pain score and in PGIC response compared with placebo . Improvements in FIQ-Total Score for the pregabalin groups were numerically but not significantly greater than those for the placebo group . Compared with placebo , all pregabalin treatment groups showed statistically significant improvement in assessment s of sleep and in patients ' impressions of their global improvement . Dizziness and somnolence were the most frequently reported adverse events . CONCLUSION Pregabalin at 300 , 450 , and 600 mg/day was efficacious and safe for treatment of pain associated with FM . Pregabalin monotherapy provides clinical ly meaningful benefit to patients with FM
While no clinical trial to date has specifically targeted fatigue , r and omized controlled trials , systematic review s , and meta-analyses indicate that treatment modalities studied in the context of other fibromyalgia symptoms could also improve fatigue .
Fatigue is a disabling , multifaceted symptom that is highly prevalent and stubbornly persistent .
Although fatigue is a frequent complaint among patients with fibromyalgia , it has not received the same attention as pain .
Reasons for this include lack of st and ardized nomenclature to communicate about fatigue , lack of evidence -based guidelines for fatigue assessment , and a deficiency in effective treatment strategies .
Fatigue does not occur in isolation ; rather , it is present concurrently in varying severity with other fibromyalgia symptoms such as chronic widespread pain , unrefreshing sleep , anxiety , depression , cognitive difficulties , and so on .
Survey-based and preliminary mechanistic studies indicate that multiple symptoms feed into fatigue and it may be associated with a variety of physiological mechanisms .